3D Bioprinting Market Size, Share & Trends Analysis Report By Technology (Magnetic Levitation, Inkjet-based), By Application (Medical, Dental, Biosensors, Bioinks), By Region, And Segment Forecasts, 2020 - 2027

Report Overview

The global 3D bioprinting market size was valued at USD 1.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 17.4% from 2020 to 2027.  The growth of this market is attributed to a limited number of organ donors, and an increasingly aging population with chronic respiratory diseases. Rising R&D investment, technological advancement, and increasing incidence of chronic diseases are also likely to boost market growth during the forecast period.

As the recent pandemic caused due to coronavirus has taken hold over the globe, even developed countries are witnessing their healthcare systems fatigued and overburdened. Hence, as a reaction to the rising cases of coronavirus, various 3D Bioprinting communities are responding to the worldwide crises by offering their respective skills to ease the burden on supply chain and governments.

As the cases of COVID-19 are increasing day by day, there has been a shortage of materials for the medical professional as well as for the general public. One of the biggest issues is lack of availability of test kits for COVID-19. Hence, various 3D bioprinting companies are manufacturing 3D printers and related software over large scale. For example, Formlabs company based in Massachusetts, U.S. is now manufacturing 100,000 nasal swabs for COVID-19 testing each day. Due to the ever-increasing cases of COVID-19, the demand for 3D bioprinting is increasing and the market for 3D bioprinting is expected to witness exponential growth.

The coronavirus pandemic has also accelerated the development of drug and vaccine testing, as scientists are harnessing new technology to help safety-testing in patients after preclinical trials are completed. With the ever-increasing cases of COVID-19, the medical world is also facing shortage of respirators and ventilators. Hence, various 3D bioprinting companies are manufacturing respirators and ventilators to overcome the shortage of these devices.

Recently CLECELL, a 3D bioprinting company, has created a respiratory epithelium model using their proprietary 3D printer U-FAB, along with other bioprinting technologies. Respiratory epithelium is a type of tissue that lines most of the respiratory tract. This epithelium acts as a barrier to pathogens and foreign particles. However, it also prevents infection and tissue injury with the help of the mucociliary elevator. Hence, with increasing incidences demand for this respiratory epithelium model, the market for 3D bioprinting is anticipated to witness growth. Owing to such innovations, the market is expected to witness higher growth over the forecast period.

Many biotherapeutic companies are using 3D bioprinting technology in order to accelerate COVID-19 research. For example, Viscient Biosciences used 3D bioprinting technology to create lung tissue which supports viral infectivity research and helps in searching for effective therapy against SARS-CoV-2, the novel coronavirus which causes COVID-19.

The Wyss Institute at Harvard University has designed a fully injection-molded nasopharyngeal swab in collaboration with the healthcare, industrial partners, and other research institutes.

3D bioprinting is witnessing demand on large scale with increasing spread of Covid-19. Hence, many pharmaceutical and biopharmaceutical participants are coming forward to help healthcare workers, physicians, and scientists in all possible ways. For example, Stratasys which is one of the leading manufacturers of 3D printer in America has manufactured face shields with the help of a 3D bioprinter. Until March 2020, they have shipped 1,00,000 face shields in the U.S.

Technology Insights

The inkjet-based segment accounted for the largest revenue share of 27.9% in 2019, as it enables the printing of complex living organs or tissues on the culture substrates with the help of biomaterials as bio-inks. Wide adoption of inkjet-based printing in the medical field is contributing to the segment’s growth. The inkjet-based technology is most widely used as compared to other 3D bioprinting technologies. It is most widely used technique in tissue bio fabrication in recent years. This work presents the research trends in inkjet printing as a bio applicable technology, especially in the fields of tissue engineering and drug delivery systems. This segment is anticipated to observe significant growth over the forecast period owing to its increasing demand and higher reliability.

Magnetic levitation segment is estimated to witness the fastest growth over the forecast period, and the syringe-based segment is likely to have the largest market share. The increasing application of this technique offered by the innovators is an important factor that promotes growth.

Also, the 3D Bioprinting products based on magnetic levitation technology are generally cost-efficient. Magnetic levitation technology is expected to solve more than 80.0% of the errors in 3D bioprinting with its advanced features, enhanced speed, and precision. These bioprinters are also used for toxicity screening, vascular muscle printing, and human cell regeneration. For instance, BioAssay has developed a tissue-like structure, with the help of magnetic levitation-based devices. The magnetic levitation based devices are most likely to witness sluggish growth over the forecast period owing to rapid increase in usage of newer technologies.

Application Insights

The medical segment accounted for the largest revenue share of 16.0% in 2019 and is anticipated to maintain its dominance over the forecast period. Vast usage of medical pills to cure various chronic diseases is propelling the growth of the market for 3D bioprinting. Moreover, growing need for the medicines and cost-efficient production of bio-drugs using this technology is further driving the segment. With increasing number of participants in the pharmaceutical industries, the demand for medical pills is increasing. Millions of people, globally, are regular users of capsules and medicinal pills. Hence, this segment is expected to witness lucrative growth over forecast period.

The tissue and organ generation segment is expected to grow at a substantial rate in the 3D bioprinting market over the forecast period.  3D bioprinting is most widely used to regenerate medicine to address the need for organs and tissue regeneration suitable for transplantation. With rising incidence of COVID-19 disease, the demand for tissue and organ generation is increasing. Due to this reason, the tissue and organ generation segment is expected to witness exponential growth over forecast period. The increasing number of COVID -19 cases globally is expected to provide new growth avenues for the key market players. Various players in the market for 3D bioprinting are engaged in developing new techniques that can overcome this pandemic effect and produce a vaccine to treat COVID-19.

Regional Insights

In Asia Pacific, the market accounted for the revenue share of 22.2% of the 3D bioprinting industry in 2019 and is expected to continue its dominance over the forecast period. Japan and China accounted for the largest revenue share in the region due to increasing incidence of COVID-19 cases and rising investment of government in R&D. As per the WHO report published in 2019, around 82,833 people were diagnosed with COVID-19 in China. Moreover, increasing the mortality rate due to COVID-19 and shortage of organ donors is further anticipated to drive the market for 3D bioprinting in this region.

In North America, the market captured a revenue share of 33.1% in 2019 and is expected to lead throughout the forecast period. The increasing incorporation of IT in the healthcare industry is estimated to stimulate the growth of market over forecast period. As per the World Meter Report 2020, around 1,378,169 active cases of Covid-19 were reported in North America until May. As there are no vaccines available until today on COVID-19, the government is spending more on research and development, in order to come with a vaccine for this condition. Due to this reason, there is an increasing demand for 3D bioprinting as this technology has been reconnoitered for drug testing and organ transplantation.

Key Companies & Market Share Insights

Key companies are stressing on research and development to develop technologically advanced products to gain a competitive edge. For instance, in November 2019, CELLINK’s developed the most advanced 3D bioprinting device, Bio X6, as well as Lumen X which produces the vascular structures. Also, Fluicell Sweden based company has launched a high-resolution bioprinting technology in both 3D and 2D forms, which is named as Biopixlar. This 3D bioprinter creates a complex tissue-like structure through which the positioning of individual cells can be controlled. It consists of some novel feature that allows users to control the system.

Companies are engaging in partnerships, mergers, and acquisitions, aiming to strengthen their product portfolio, manufacturing capacities, and provide competitive differentiation. For instance, in November 2019, BASF GmbH acquired Sculpteo which is a 3D printing service provider. This acquisition is anticipated to help BASF to market and establish new industrial 3D printing materials more quickly. Some of the prominent players in the 3D bioprinting market include:

• Envisiontec, Inc.

• Organovo Holdings, Inc.

• Inventia Life Science PTY LTD

• Poietis

• Vivax Bio, LLC

• Allevi

• Cyfuse Biomedical K.K.

• 3D Bioprinting Solutions

• Cellink Global

• Regemat 3D S.L.

3D Bioprinting Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global 3D bioprinting market report on the basis of application, technology, and region:

• Technology Outlook (Revenue, USD Million, 2016 - 2027)

  • Inkjet-based

  • Magnetic Levitation

  • Syringe-based

  • Laser-based

  • Others

• Application Outlook (Revenue, USD Million, 2016 - 2027)

  • Medical

    • Tissue and organ generation

    •  Medical pills

    •  Prosthetics and implants

  • Dental

  • Biosensors

  • Consumer/Personal Product Testing

  • Bioinks

  • Food and Animal Product

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE